NCT01699464

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 211 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.

Conditions

• Ocular Hypertension
• Open-angle Glaucoma

Interventions

Type	Name	Description
DRUG	AR-12286 Ophthalmic Solution 0.7%	Ophthalmic Solution
DRUG	AR-12286 Ophthalmic Solution 0.5%	Ophthalmic Solution
DRUG	Timolol maleate ophthalmic solution 0.5%	Ophthalmic Solution

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2012-10-03
• Last updated: 2023-08-22